Latest Cervical intraepithelial neoplasia Stories
Company Expands IP Portfolio Covering Test Methods to Identify Chromosomal Abnormalities including 3q (TERC) and 5p (TERT) in Cervical Cells GAITHERSBURG, Md., Oct.
SEATTLE, Aug. 25, 2014 /PRNewswire/ -- Trovagene, Inc.
A study published online in the International Journal of Cancer earlier this month describes a novel approach to preventing cervical cancer based on findings showing successful reduction in the risk of cervical cancer after removal of a discrete population of cells in the cervix.
Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses PLYMOUTH MEETING, Pa., July 23, 2014 /PRNewswire/
LAVAL, QC, June 10, 2014 /CNW Telbec/ - Roche announced that Health Canada approved the cobas® 4800 HPV (Human Papillomavirus) Test for use as a first-line primary screening test for cervical
NORTH BRUNSWICK, N.J., Feb.
polyDNA urges military healthcare providers to recommend Gene-Eden-VIR, an HPV remedy, to infected service women Rochester, NY (PRWEB) March 12, 2013
Testing women to see if they are cured of HPV (the virus that can cause genital warts and cervical cancer) following treatment for abnormal cells on the surface of the cervix is more effective and cheaper than cytology testing (cervical screening) alone.
HIV-infected and uninfected women with normal cervical cytology (Pap test) and a negative test result for oncogenic (tumor inducing) human papillomavirus DNA at study enrollment had a similar risk of cervical pre-cancer and cancer after 5 years of follow-up.
- A transitional zone between two communities containing the characteristic species of each.